Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Flexion Therapeutics, Inc. (NASDAQ: FLXN).

Full DD Report for FLXN

You must become a subscriber to view this report.


Recent News from (NASDAQ: FLXN)

Flexion Therapeutics (FLXN) CEO Michael Clayman on Q1 2018 Results - Earnings Call Transcript
Flexion Therapeutics, Inc. (FLXN) Q1 2018 Earnings Conference Call May 08, 2018, 04:30 PM ET Executives David Arkowitz - CFO Dan Deardorf - SVP of Commercial Michael Clayman - Co-Founder, President, CEO Scott Young - VP of Corporate Communications & IR Analysts Dan Bu...
Source: SeekingAlpha
Date: May, 08 2018 22:46
Flexion Therapeutics beats by $0.23, misses on revenue
Flexion Therapeutics (NASDAQ: FLXN ): Q1 EPS of -$1.10 beats by $0.23 . More news on: Flexion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:05
Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights
Company booked net ZILRETTA ® sales of $2.2 million in Q1 Positive developments in Medicare reimbursement with CMS issuing Q code for ZILRETTA (effective 7/1/18) and recommending dedicated J code (effective 1/1/19) Pivotal Phase 3 trial results published in the Journal o...
Source: GlobeNewswire
Date: May, 08 2018 16:01
Flexion Therapeutics Names David Arkowitz as Chief Financial Officer
BURLINGTON, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that David Arkowitz has been named Chief Financial Officer (CFO). Mr. Arkowitz brings more than 25 years of finance and operations leadership experience in the life sciences and biot...
Source: GlobeNewswire
Date: May, 07 2018 07:30
Permanent reimbursement for Flexion's Zilretta established in U.S.
Flexion Therapeutics (NASDAQ: FLXN ) announces that the U.S. Centers for Medicare and Medicaid Services (CMS) has established a permanent reimbursement code for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) that will go into effect January 1, 2019. More news o...
Source: SeekingAlpha
Date: May, 04 2018 08:15
Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS
BURLINGTON, Mass., May 04, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the Centers for Medicare and Medicaid Services (CMS) has included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) on its list of products that have been rec...
Source: GlobeNewswire
Date: May, 04 2018 07:30
2 Attractive Biotech Stocks To Buy Now
T he Guide says there is an art to flying", said Ford, "or rather a knack. The knack lies in learning how to throw yourself at the ground and miss .” ― Douglas Adams, Life, the Universe and Everything Today, we profiled two biotech stocks that we believe are set up to do w...
Source: SeekingAlpha
Date: May, 02 2018 10:25
Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018
BURLINGTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, May 8, 2018. Flexion’s management will host ...
Source: GlobeNewswire
Date: April, 30 2018 16:30
Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress
Results from preclinical osteoarthritis (OA) models demonstrate relief of pain, functional improvement and suggest disease-modifying efficacy following a single intra-articular injection BURLINGTON, Mass., April 29, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) tod...
Source: GlobeNewswire
Date: April, 29 2018 09:00
Flexion up 2% on new Zilretta data in OAK
Flexion Therapeutics ( FLXN +2.3% ) is up, albeit on light volume, on the heels of its announcement of additional data from the open-label Phase 3b study evaluating ZILRETTA (triamcinolone acetonide) in patients with osteoarthritis of the knee (OAK). The results will be presented tomorro...
Source: SeekingAlpha
Date: April, 26 2018 11:12

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1826.5626.6426.8625.95672,590
2018-05-1726.5626.6426.8625.95672,590
2017-05-1618.4318.0718.5417.55818,406
2017-05-1519.4118.2919.5318.25650,940
2017-05-1219.4419.3119.5019.03434,313

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2523,78266,67235.6701Short
2018-05-2465,573138,39047.3828Short
2018-05-2373,052144,19250.6630Short
2018-05-2278,531146,15453.7317Short
2018-05-21101,370163,90161.8483Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FLXN.


About Flexion Therapeutics, Inc. (NASDAQ: FLXN)

Logo for Flexion Therapeutics, Inc. (NASDAQ: FLXN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: FLXN)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 08 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 08 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 08 2018

       

       


      Daily Technical Chart for (NASDAQ: FLXN)

      Daily Technical Chart for (NASDAQ: FLXN)


      Stay tuned for daily updates and more on (NASDAQ: FLXN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: FLXN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FLXN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of FLXN and does not buy, sell, or trade any shares of FLXN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/